Sanofi a global integrated healthcare leader, focused on patients' needs

SANOFI
A global
integrated
healthcare
leader,
focused
on patients'
needs
CORPORATE PRESENTATION 2013

CONTENTS
OUR GROWTH PLATFORMS INNOVATION IN R&D OUR RESPONSIBILITY CORPORATE PRESENTATION 2013

CORPORATE PRESENTATION 2013 BMP Sunstone, Medley , Merial, Nepentes, Zentiv a, Kendricks, Oenobiol, Chattem, HERITAGE
Acambis, Sy mbion, Shantha 2008-2010
A long tradition Sanof i-av entis Sanof i-Sy nthélabo CORPORATE PRESENTATION 2013 A diversified
AT A GLANCE
of medicines, vaccines and innovative therapeutic solutions €34.9bn
We are a global integrated healthcare company engaged in the research,
development, manufacturing and marketing of healthcare products.
(1) As of December 31, 2012 CORPORATE PRESENTATION 2013 We act with our partners to protect health, COMMITMENT
enhance life and respond to the potential healthcare needs of 7 billion people around OUR
AMBITION
With our global footprint and commitment
to improving access to medicines
and healthcare, we work tirelessly to make
a difference to people's lives every day
and transform scientific innovations into
therapeutic solutions for patients.
CORPORATE PRESENTATION 2013 OUR GROUP OUR STRATEGY SUSTAINABLE
A GLOBAL HEALTHCARE LEADER LONG-TERM
WITH SYNERGISTIC PLATFORMS INCREASE
INNOVATION IN R&D
SEIZE
EXTERNAL GROWTH
OPPORTUNITIES
ADAPT
THE GROUP TO FUTURE
CHALLENGES & OPPORTUNITIES
CORPORATE PRESENTATION 2013 OUR GROWTH PLATFORMS CORPORATE PRESENTATION 2013 OUR GROWTH PLATFORMS Emerging markets Diabetes solutions Consumer Healthcare Other Innovative Products CORPORATE PRESENTATION 2013 OUR GROWTH PLATFORMS EMERGING
The strong presence of Sanofi in Emerging Markets supports access to health by proposing Latin America Asia a wide range of medicines at adapted prices. East Eastern Europe Russia Turkey Healthcare Company in Emerging Markets (1) IMS Health (IMS Midas 2012) CORPORATE PRESENTATION 2013 DIABETES
SOLUTIONS
Million people
million people have diabetics in Africa Africans who
are diabetic
it is anticipated 552 Kwa-Zulu Natal & Gauteng has the highest prevalence
CORPORATE PRESENTATION 2013 OUR GROWTH PLATFORMS A leadership position with Sanofi Pasteur VACCINES
1 billion
doses of vaccine to immunise more than 500 mil ion people doses of vaccines more than 500 million CORPORATE PRESENTATION 2013 OUR GROWTH PLATFORMS Solutions to manage CONSUMER
HEALTHCARE
health in the everyday life all around the world. With a diversified
(1) Nicholas Hall 2012 portfolio of local brands
Allergy:
Maalox®, No Spa® Essentiale Enterogermina® Feminine hygiene:
CORPORATE PRESENTATION 2013 OUR GROWTH PLATFORMS innovation-driven company, providing
a comprehensive
employees worldwide range of products
to enhance
Present in more than the health,
well-being
and performance
of a wide range of animals. production sites companion avian animal CORPORATE PRESENTATION 2013 RARE DISEASES
RARE DISEASES
GENZYME:
Homozygous familial hypercholesterolemia RARE
DISEASES
AND
MULTIPLE
SCLEROSIS

MULTIPLE SCLEROSIS
CORPORATE PRESENTATION 2013 OUR GROWTH PLATFORMS INNOVATIVE
PRODUCTS
atrial fibrillation hematopoietic cancer colorectal cancer CORPORATE PRESENTATION 2013 INNOVATION IN R&D CORPORATE PRESENTATION 2013 INNOVATION IN R&D We have to be where the pathologies and the patients' needs are. ACCELERATE
INNOVATION
We act as one to discover and FOR PATIENTS
develop therapies that prevent, treat and cure disease. We are focused on vaccines and 7 key therapeutic areas: Multiple Sclerosis projects and vaccines under clinical development Cardio-Metabolic Potential launches between 2012 and 2015 CORPORATE PRESENTATION 2013 INNOVATION IN R&D ACCELERATE
INNOVATION
FOR
Translational Medicine PATIENTS
to create deeper interaction between clinic PATIENTS
and fundamental research and improve diagnosis and patient care. PATIENTS
HOSPITALS
BIOPHARMA
GOVERNMENT
This health ecosystem places the patient and their needs at the heart of the priorities. CORPORATE PRESENTATION 2013 OUR RESPONSIBILITY CORPORATE PRESENTATION 2013 OUR RESPONSIBILITY Improve access to medicines by promoting TO QUALITY
comprehensive management of diseases HEALTHCARE
combining prevention, diagnosis and treatment in developing countries. IT IS SANOFI'S COMMITMENT TO REDUCE of the population Health inequalities through Childhood Cancer, Maternal and Infant Mortality. Promoting quality care by fighting against counterfeit medicines. CORPORATE PRESENTATION 2013 To "move further" the human right to health becomes disease areas
a reality, Sanofi develops for Access
programs to improve access TO MEDICINES
to Medicines
to medicines for people in developing countries. Malaria Tuberculosis Neglected Tropical Diseases Leishmaniasis Approach
Information and education, Medicines adapted to patients needs, and vaccine
Tiered pricing policy preventable
diseases
for therapeutic innovation Industrial expertise CORPORATE PRESENTATION 2013 OUR RESPONSIBILITY NEGLECTED
TROPICAL
DISEASES
TO MEDICINES
years partnership with WHO in the fight against Neglected Tropical Diseases, with a total of eliminate sleeping sickness by 2020. lives saved from sleeping sickness. is part of our DNA CORPORATE PRESENTATION 2013 OUR RESPONSIBILITY REDUCING
HEALTH
INEQUALITIES
SANOFI
ESPOIR
FOUNDATION
Childhood cancers Access to healthcare in developing countries infant mortality for excluded populations STAND UP FOR
PRECARITY
AFRICAN MOTHERS
AND HEALTH
19 projects in 16 countries Initiated in 2010 Ease and improve access in partnership with UICC in partnership with to healthcare for socially (International Union Against the African Medical
excluded populations & REsearch Foundation
in France through a partnership with the Red
Cross, Médecins du Monde
and the Samu Social.
CORPORATE PRESENTATION 2013 OUR RESPONSIBILITY Laboratory dedicated
to the analysis of
HEALTHCARE
to protecting
counterfeit products the safety
of patients
by fighting
counterfeit
medicines.
products have been analysed Campaign with Air France
to highlight the danger
of counterfeit medicines
CORPORATE PRESENTATION 2013 CORPORATE PRESENTATION 2013 NET SALES
TOTAL SALES
TOTAL SALES
(in million euros) OF GROWTH PLATFORMS
BY GEOGRAPHICAL
(in million euros) ZONE (in million euros)
33,389 34,947
CORPORATE PRESENTATION 2013 EMPLOYEES BY GEOGRAPHIC ZONE
workforce:
more than
employees
Europe (exclu. France)
28,154
CORPORATE PRESENTATION 2013 COUNTRIES
13 sites vaccines
Industrial
10 sites in Europe
7 sites in North America
R&D sites
1 site in Asia
CORPORATE PRESENTATION 2013 This corporate presentation Forward Looking Statements
is available for all employees This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, in the Sanofi Group. statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", It may be used internally "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various or externally for presentations risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and of the Group, either in whole developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post or in part, as needed. marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially The information is taken successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, from Form 20-F 2012, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed annual results 2012 and press under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2012. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. Photography credits: Pierre-Olivier Callede / CAPA Pictures – Gil Corre - Eric Larrayadieu / Interlinks Image - Guillaume Ramon / Capa
Further information is available Pictures - Eric Larrayadieu / Interlinks Image - Urbanhearts / Fotolia – f.belge / CAPA Pictures - Pierre-Olivier Callede / CAPA Pictures –
on www.sanofi.com Sanofi Pasteur/ Aiko Kawamura – Denis Félix - Jean-Michel Labat / Interlinks Image - George P. DeTorres / MultiVu - Cedric Arnold / Capa
Pictures – Denis Félix / Corbis - Guillaume Ramon / Capa Pictures - Franck Thibault – Gil Corre– Sanofi – AMREF – Samu social - Image
Source/Corbis
CORPORATE PRESENTATION 2013 Further information: www.sanofi.com SANOFI HEADQUARTERS 54, RUE LA BOÉTIE 75008 PARIS, FRANCE TEL. +33 (0)1 53 77 40 00

Source: http://www.sanofi.co.za/l/za/en/extlink.jsp?el=89795009-65B6-4B47-9623-ED833D010FF9